CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse Other stock markets 21:00:02 16/04/2026 BST			5-day change	1st Jan Change
176.94 ^USD	-2.00%		+0.79%	-11.30%

04-14	Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says	MT
04-14	Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $200, Maintains Overweight Rating	MT

Transcript : Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 10

Published on 06/04/2025 at 04:50 pm BST - Modified on 06/04/2025 at 06:05 pm BST

S&P Capital IQ

Presenter Speech
David Windley (Analysts)

Hi. Good morning. I'm Dave Windley with Jefferies Healthcare Equity Research. Welcome to Jefferies 2025 New York Conference. Pleased to have you here. I

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Charles River Laboratories International, Inc.

04-14	Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says	MT
04-14	Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $200, Maintains Overweight Rating	MT
04-14	RBC Initiates Charles River Laboratories International at Outperform With $215 Price Target	MT
04-08	Baird Raises Price Target on Charles River Laboratories International to $200 From $197, Maintains Outperform Rating	MT
03-31	AI-led selloff in contract research firms may be misjudging disruption risk	RE
03-12	Locus Cell Co., Ltd. And Charles River Laboratories Sign Memorandum Of Understanding For Cell And Gene Therapy Collaboration	CI
03-10	Charles River Laboratories International, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 10:00 AM
03-09	Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193	MT
03-05	Therna Biosciences, Inc. Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics	CI
03-03	Charles River Laboratories International, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM
02-25	IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE : CRL) for $155 million.	CI
02-25	GI Manager L.P. signed a definitive agreement to acquire Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc..	CI
02-25	UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating	MT
02-25	Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated	MT
02-25	Charles River raises annual profit view as it sells underperforming assets	RE